Recipharm’s solid dose facility in Fontaine, France has been approved for supply of manufactured products to the Japanese pharmaceuticals market following a recent inspection by the Japanese drug agency, PMDA. The Fontaine site, acquired in 2009 from Solvay Pharma (now Abbott), is also approved to supply to the U.S. and has a distribution center for delivery to pharmacy level in France.
 
Stéphane Guisado, general manager of the Fontaine site, said, “We are very pleased to have secured this approval. Supplying products to Japan involves carrying out a substantial number of additional activities and meeting stringent requirements for enhanced quality control and we have met these challenges head on. We were also able to draw upon experience from other Recipharm sites, which are already supplying this key market. As a result of this approval, we are now in a good position to further support other customers with their plans to penetrate and expand sales in specific pharmaceutical markets within Japan.”